Introduction
Secondary hyperparathyroidism is common in end stage renal disease and may cause disabling bone problems, growth retardation, and other complications.1-3 Although the role of dietary phosphate in the pathogenesis of secondary hyperparathyroidism in experimental uraemia is well established,4-6 successful long term suppression of secondary hyperparathyroidism by dietary phosphate restriction has not been achieved in adults or children with chronic renal failure. Very low phosphate diets are unpalatable, and oral aluminium compounds used to bind dietary phosphate to prevent absorption carry a risk of aluminium toxicity, particularly in young children. 7 Calcium carbonate has been used as an alternative phosphate binder,9 10 but long term clinical trials have not been reported. We studied the use of high dose phosphate binders and mild dietary phosphate restriction for the suppression of secondary hyperparathyroidism and compared aluminium hydroxide and calcium carbonate as phosphate binders in a randomised crossover study of children with chronic renal failure. The effects of the correction of secondary hyperparathyroidism on growth, renal function, and anaemia are reported.
Patients and methods
Twelve children aged 5-15 years (mean 11 years) in stable chronic renal failure were studied. They were selected for the study so that both mild renal insufficiency and severe chronic renal failure were represented. Table I summarises the clinical details of the children at the initial assessment.
The children had previously received reduced dietary protein and phosphate intakes with energy supplementation in the form of glucose polymer (Caloreen), and aluminium hydroxide had been given as a phosphate binder (mean dosage 1 3 g/day) with vitamin D supplementation as dihydrotachysterol (0-25 mg/m2/day; this form of vitamin D was routinely used in such children when the trial began, although now we prefer to use la or 1,25-dihydroxycholecalciferol). 24 hour urine specimens compared well with the method described by Bijvoet, which utilises three hour urine collections obtained in the morning while fasting and during a moderate diuresis13 (n=40; r=087; p<0001).
After the initial three months the diet was stabilised with moderate phosphorus restriction while maintaining protein intake at the previous level. The children were advised to reduce the intake of dairy protein, especially skimmed milk, cheese, and milk chocolates. Low phosphorus milk substitutes and special low phosphorus baking powder were provided. Food tables were given so that food items with a low phosphorus content could be chosen-for example, fine cereals contain less phosphate than cereals with bran. If the child had a particular liking for a food with a high phosphorus content it was allowed in moderation and the dosage of the phosphate binder used increased accordingly. The Eleven of the 12 repeat bone biopsy specimens were technically satisfactory. Mild to moderate features of osteitis fibrosa with no osteomalacia were present in all the specimens at the beginning of the study. Osteitis fibrosa definitely improved in four patients (mean parathyroid hormone concentration: before 1300 (SE 450), after 430 (140) ng/l), deteriorated in two (mean parathyroid hormone concentrations: before 1300 (280), after 880 (130) ng/l), and did not change in five (mean parathyroid hormone concentration: before 1150 (210), after 300 (80) ng/l). No osteomalacia was apparent after treatment. The two patients in whom bone disease worsened were those who were less compliant with their phosphate control. Plasma phosphate concentration at the end of the study was 1-6 mmol/l (5-0 mg/100 ml) in both patients, whereas the mean for the rest of the group was 1-25 (SE 0 05) mmol/l (3 9 (0-15) mg/100 ml). Total Phosphate retention in uraemia is implicated in the development of secondary hyperparathyroidism and in alterations in the metabolism of vitamin D. An increase in plasma phosphate concentration as the glomerular filtration rate falls is associated with a reduction in the plasma concentration of ionised calcium with stimulation of parathyroid hormone, and in addition phosphorus mediated suppression of renal 25-hydroxyvitamin D, la-hydroxylase leads to a decrease in the plasma concentration of 1,25-dihydroxyvitamin D., which reduces both the gut absorption and bone reabsorption of calcium, also leading to stimulation of parathyroid hormone release. 19 With mild renal insufficiency the increase in parathyroid hormone is enough to return the plasma phosphate concentration to normal, but severe chronic renal failure is associated with a rise in the plasma phosphate value, which may result in a high calcium x phosphate product, leading to nephrocalcinosis and rapid deterioration of renal function. 20 In experiments in dogs secondary hyperparathyroidism was prevented by limiting phosphate intake in proportion to the reduction in renal function in conjunction with supplementation with vitamin D." In addition, restriction of dietary phosphate in uraemic rats led to increased survival and a reduction in renal damage. conventionally.
Aluminium toxicity with encephalopathy and severe osteodystrophy has been reported in children with uraemia in whom the only major source of aluminium intake was from the gastrointestinal absorption of phosphate binders containing aluminium.8 26-28 Moriniere et al gave calcium carbonate to adult uraemic patients receiving haemodialysis and obtained satisfactory control of hyperphosphataemia and hyperparathyroidism with a reversal of hyperaluminaemia which had resulted from treatment with aluminium hydroxide. 10 The possibility that increased calcium absorption may lead to hypercalcaemia causes concern, but it would seem reasonable to substitute calcium carbonate for aluminium hydroxide after initial control of plasma phosphate concentration has been achieved. In our study episodes ofhypercalcaemia were as common with aluminium hydroxide as with calcium carbonate and occurred only after several months of treatment, perhaps due to altered vitamin D metabolism resulting from control of phosphate retention.
The bone biopsy changes corresponded well to the clinical response. Definite improvement of bone disease occurred in four patients in whom suppression of hyperparathyroidism was adequate. Although the histological picture was not normal at the end of 12 months of treatment, this represented only six months of adequate suppression of parathyroid hormone values. Bone disease deteriorated in two patients who were less compliant, and the remaining five patients with no appreciable change did not have severe degrees of bone disease at the beginning of the study.
The improved growth of the children was encouraging, but since many of the children were entering puberty the results should be interpreted cautiously. Correction of hyperparathyroidism has been reported to improve growth in children receiving haemodialysis, but control studies are not available. 29 Severe renal osteodystrophy contributes to growth retardation in advanced renal failure, but milder degrees of bone disease have not been shown to correlate with growth failure.30 31 Though we have shown that it is possible to suppress secondary hyperparathyroidism, at least over a 12 month period, it is not certain that such suppression can be maintained over a longer period. It would seem advisable to attempt to prevent the development of secondary hyperparathyroidism by control of phosphate absorption early in the development of renal insufficiency, particularly in very young children. In this respect the simple biochemical determinations such as plasma phosphate concentration and fractional phosphate excretion used in this study are easily applied and generally available.
Renal function did not change appreciably during the 15 months of the study; nevertheless, while this was encouraging, no conclusion about the effect of secondary hyperparathyroidism on renal function can be drawn because glomerular filtration rate as estimated from the plasma creatinine concentration was not significantly different 12 months before the study started in the 10 patients in whom data were available.
In conclusion, secondary hyperparathyroidism was suppressed over 12 months in children with preterminal chronic renal failure using a regimen of mild dietary phosphate restriction and high dose phosphate binders. Calcium carbonate was as effective as aluminium hydroxide as a phosphate binder and an improvement in growth was noted. The regimen was well tolerated with few and easily reversible side effects. In view of the risk of aluminium toxicity we recommend that high dose calcium carbonate should be used as the phosphate binder in patients with chronic renal failure after initial reduction of plasma phosphate with a low phosphate diet and aluminium hydroxide. We suggest that control of secondary hyperparathyroidism should be initiated early in the development of chronic renal failure when a definite rise in plasma parathyroid hormone concentration is detected or the tubular reabsorption of phosphate falls below normal. In children this may occur when the glomerular filtration rate falls below 45 ml/min/1-73 M2.
